MAX Chat
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
9/10
|
11.19 | 98.17 | -88.6% | 0 | 0% |
| P/S |
|
1.08 | 15.43 | -93% |
|
|
| P/BV |
|
1.07 | 5.38 | -80.1% |
|
|
| P/FCF |
|
0 | -14.74 | -100% |
|
|
| Ev/Ebitda |
|
15.48 | 18.15 | -14.72% |
|
|
| Ev/S |
|
2.13 | 17.01 | -87.46% |
|
|
| Ev/FCF |
|
0 | 13.46 | -100% |
|
|
| E/P |
|
0.054 | 0.0234 | 130.53% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
4/10
|
13.28 | -42.13 | -131.51% | 13.28 | 0% |
| ROE |
|
8.61 | 2.36 | 264.84% |
|
|
| ROA |
|
2.25 | 2.84 | -20.73% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
9.59 | -55.5 | -117.28% |
|
|
| ROCE |
|
0 | 1.47 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
0/10
|
5.22 | 0.934 | 458.58% | 5.22 | 0% |
| Nеt Debt/Ebitda |
|
0 | -0.0069 | -100% |
|
|
| Debt/Ratio |
|
0 | 0.1161 | -100% |
|
|
| Debt/Equity |
|
0 | 0.9024 | -100% |
|
|
| Debt/Net Income |
|
7.23 | 6.08 | 18.79% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
5.85/10
|
2.34 | 0.2956 | 691.66% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1 | -100% | ||
| DSI |
|
1 | 0.6626 | 50.92% |
|
|
| Average dividend growth |
|
0 | 0.3625 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 1.51 | -100% |
|
|
| Average percentage for payments |
|
0 | 85.51 | -100% |
|
|
| Difference from average difference in sector |
|
2.04 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
3/10
|
0 | 25.64 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
0 | 13.87 | -100% | ||
| Growth impulse Net Income in 5 years |
|
0 | 253.87 | -100% | ||
| Growth impulse FCF in 5 years |
|
0 | 62.53 | -100% | ||
| Growth impulse EPS in 5 years |
|
0 | 24.33 | -100% |
IP Score
4.73/10
